Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

NCT03121586 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

995

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Pimavanserin

Sponsor

ACADIA Pharmaceuticals Inc.